Acadia Pharmaceuticals' Rebranding and AI Integration
Acadia Pharmaceuticals CEO Catherine Owen Adams discusses the company's recent rebrand, expansion into rare disease marketing, and the role of AI in its strategy.
Neurological biotech Acadia Pharmaceuticals has rolled out a rebrand as it seeks to expand into the rare disease space, with AI playing a major role in its marketing strategy.
- Rebranding to expand into rare disease space
- AI integration in marketing strategy
- Challenges and benefits of marketing as a smaller biotech
Acadia CEO Catherine Owen Adams shares her insights on the company's rebrand, expansion, and AI usage.
Adams draws on her marketing background to steer the company into 2026, addressing the opportunities and challenges ahead.
Author's summary: Acadia Pharmaceuticals rebrands and integrates AI.